No Data
Gossamer Bio Management to Meet With Oppenhiemer
Bullish Outlook on Gossamer Bio's Seralutinib Efficacy and Market Potential
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Gossamer Bio Announced Two Oral Presentations And Poster Presentation With Data Relevant To Seralutinib At European Respiratory Society Congress 2024
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
loading...
Rockhoundj : Whaddya think about FRGT$Freight Technologies (FRGT.US)$ ?
FattyChick OP Rockhoundj : From the last RS earlier this year, the next RS coming soon
FattyChick OP Rockhoundj : If you really want to get a position, entry 0.108 - 0.11.
TP 0.136.
Rockhoundj FattyChick OP : I’m holding just under .13
With a tight stop loss
Jenna Ragan : these look nice
View more comments...